Novo Nordisk A/S (0TDD.L)
| Previous close | 123.35 |
| Open | 125.06 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 124.20 - 125.20 |
| 52-week range | 68.37 - 142.93 |
| Volume | |
| Avg. volume | 22,405 |
| Market cap | 2.843B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 0.41 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Bloomberg
Investors Pile Into Amgen in Search of Next Obesity Drug Payout
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeJudge Threatens Trump With Jail Over Gag Order ViolationsTreasury Rally Risks Running Into a $125 Billion Brick WallBuffett Praises Apple After Trimming It, Drops Paramount StakeThe shares s
- Yahoo Finance
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
- Insider Monkey
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript May 2, 2024 Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77. NVO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day! And thank […]
